Arcturus Therapeutics, Marina Biotech deal

Marina sold its Unlocked Nucleobase Analog (UNA) patents for the development of RNAi therapeutics to Arcturus. Marina retains a non-exclusive license to the technology. UNAs are acyclic ribonucleoside analogs in which the bond between the C2' and C3' atoms is broken for flexibility. Arcturus said it is focused on developing and commercializing lipid nanoparticle (LNP) siRNA drug delivery systems for the Orphan liver disease market. The partners declined to disclose financial terms. ...